The US Food and Drug Administration (FDA) has approved paliperidone (Invega; Ortho-McNeil-Janssen Pharmaceuticals) for the treatment of schizophrenia in adolescent patients aged 12 to 17 years. Paliperidone is an atypical antipsychotic and was originally approved in 2006 for the treatment of schizophrenia in adults.
Paliperidone is a centrally active dopamine D(2)- and serotonergic 5-HT(2A)-receptor antagonist. The extended-release formulation allows once-a-day dosing. The controlled release rate provides gradual ascending plasma concentrations peaking at 24 hours after the first dose and minimal fluctuation thereafter. Steady-state levels are obtained after 4 daily doses.
source:medscape
Paliperidone is a centrally active dopamine D(2)- and serotonergic 5-HT(2A)-receptor antagonist. The extended-release formulation allows once-a-day dosing. The controlled release rate provides gradual ascending plasma concentrations peaking at 24 hours after the first dose and minimal fluctuation thereafter. Steady-state levels are obtained after 4 daily doses.
source:medscape
No comments:
Post a Comment